A three-person company emerging from Y Combinator says it can deploy autonomous robots in pharmaceutical laboratories within seven days of initial contact, an unusually aggressive timeline in an industry where installation cycles typically span months.
Neuromorphic, based in San Francisco, announced in August that its mobile robots are already operating around the clock at what it describes as "the largest autonomous lab in the US," completing over 2,000 tasks. The company emphasizes compatibility with existing infrastructure, though independent verification of its deployment claims is not available. The claim raises questions about how quickly laboratory automation can scale, particularly as drug developers face mounting pressure to accelerate research timelines.
The problem the startup is tackling isn't exactly glamorous. Lab technicians at biotechnology companies often work nights and weekends shuttling samples between instruments—centrifuges to freezers, incubators to analyzers—while millions of dollars in equipment sits idle during off-hours. Neuromorphic's pitch centers on robots that handle the overnight shift.
Founder and CEO Vatan Aksoy Tezer, who previously led robotics teams at Augmentus and worked on navigation systems deployed across more than 100 robots at KABAM Robotics, describes the company's approach as building an "embodiment-agnostic brain." The architecture packages sensors, computing power, and software onto mobile platforms. An onboard language model orchestrator stitches together what the company calls reusable skills: navigate to a station, grasp objects, open refrigerators, visually inspect work areas. Scientists communicate with the system through Slack, email, or phone calls.
"Our goal is to make deploying robots in wet labs and other physical industries as easy as onboarding a new employee," Tezer wrote in the launch announcement.
Whether that comparison holds remains to be seen. The company said it deployed a robot at an unnamed biotechnology company within a week of first conversation, though it hasn't disclosed how much customization or troubleshooting happened after that initial deployment. By late August, the startup reported what it states as a 97%+ success rate across those 2,000-plus completed tasks, a figure that would be impressive if sustained at scale, though no independent audit or validation is available.
Neuromorphic hasn't identified the facility where its robot operates, describing it only as the country's largest autonomous laboratory. The reference appears to be to a facility such as Medra's 'Lab 001,' though the company has not explicitly confirmed this relationship. The company is competing in a space where definitions of "autonomous" vary widely depending on who's talking.
The lab automation sector has been heating up. Opentrons partnered with NVIDIA earlier this year to accelerate what it calls physical-AI robotics, with Opentrons CEO James Atwood suggesting that continuous experimental loops running across thousands of facilities could compress discovery timelines "from years to weeks." Automata inked a deal with Beckman Coulter Life Sciences to build AI-ready instrument workflows. OpenAI demonstrated in January that language model-driven robots could achieve 89% of human performance on cloning protocols, though those results came under controlled conditions.
The competitive landscape includes established liquid-handling vendors like Hamilton and Tecan, orchestration platform Biosero, and cloud lab operators such as Strateos and Emerald Cloud Lab. Those players largely focus on stationary workstations. Neuromorphic positions its mobile robots as handling what it calls the "physical last mile" between instruments, an appealing concept if the execution matches the ambition.
Co-founder and CTO Ege Doğanay brings research experience from Bilkent University and a research fellowship at Nanyang Technological University. Co-founder and COO Cem Toker previously launched ErgoFlow and developed calibration algorithms at Zeeko. The team's technical credentials are solid, though turning robotics expertise into a scalable business has tripped up plenty of well-credentialed founders before them.
Neuromorphic participates in NVIDIA's Inception program for startups and carries Y Combinator's backing. The company's website lists two robot models—Darwin, an autonomous mobile robot, and Mendel, described as a wheeled humanoid—both tagged as "coming soon," suggesting the technology is still evolving.
The broader question hanging over lab automation isn't whether robots can perform individual tasks reliably. Many can. It's whether they can adapt quickly enough to the chaotic reality of working labs, where protocols shift, equipment breaks down, and edge cases multiply faster than programmers can anticipate them. Neuromorphic's one-week deployment claim will be tested as it attempts to move beyond early adopters into laboratories with less tolerance for experimentation.
